Related Experiment Video

Updated: Jun 13, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Integrin-linked kinase (ILK) in hematologic malignancies: Bridging molecular mechanisms to therapeutic innovation

Omer Qutaiba B Allela1, Abdulkareem Shareef2, Ashishkumar Kyada3

  • 1College of Pharmacy, Alnoor University, Mosul, Iraq.

Bioimpacts : BI
|June 12, 2026
PubMed

Insights

Integrin-linked kinase (ILK) drives therapy resistance in blood cancers by mediating microenvironmental protection. Inhibiting ILK overcomes resistance, sensitizes cells to treatments, and targets cancer stem cells.

Area of Science:

  • Hematology
  • Molecular Biology
  • Cancer Research

Background:

  • Therapy resistance is a major challenge in hematologic malignancies.
  • Integrin-linked kinase (ILK) is implicated in cell adhesion and signal transduction.
  • ILK's role in hematologic malignancies differs from its role in solid tumors.

Purpose of the Study:

  • To review ILK as a therapeutic target in hematologic malignancies.
  • To explore ILK's role in mediating microenvironmental protection and therapy resistance.
  • To present ILK as a strategy to overcome treatment resistance.

Main Methods:

  • Systematic analysis of ILK's structural properties.
  • Examination of ILK expression patterns in malignant cells.
  • Investigation of ILK's downstream signaling and microenvironmental interactions.

Main Results:

  • ILK expression is significantly higher in malignant blood cells.
  • ILK connects microenvironmental signals to intracellular survival pathways.
  • ILK inhibition disrupts survival pathways and sensitizes resistant cells.

Conclusions:

  • ILK is a promising therapeutic target for overcoming resistance in hematologic malignancies.
  • ILK inhibition selectively targets therapy-resistant leukemic stem cells.
  • Targeting ILK offers a framework for innovative therapeutic strategies.
Keywords:
Hematologic malignanciesIntegrin-linked kinaseLeukemic stem cellsTherapy resistanceTumor microenvironment

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
Lineage Commitment01:21

Lineage Commitment

Commitment is the  process whereby stem cells: